Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Benelux Price Negotiations: Beware of EU-Wide Pricing Policy, warns Germany

This article was originally published in Scrip

Executive Summary

Manufacturers could find themselves talking with multiple EU member states at once to get their orphan drugs to patients if a pilot on joint pricing negotiations is a success. Currently Belgium, the Netherlands and Luxemburg are developing the pilot, but more countries are looking at whether they may want to join in.

Advertisement

Related Content

"Crazy" European Orphan Drug Pricing System Has To End

Topics

Advertisement
UsernamePublicRestriction

Register

SC030241

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel